Vicarious Surgical names Stephen From as new CEO

Vicarious Surgical Inc. (NYSE: RBOT) announced the appointment of Stephen From as chief executive officer and board member, effective August 7, 2025. Adam Sachs, the current CEO and co-founder, will transition to president while remaining on the board and leadership team.

From brings over 20 years of healthcare and financial industry experience. He most recently served as CEO of Aruna Bio and previously led Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) as president and CEO from October 2005 through February 2021, then as executive chairman until January 2022. During his tenure at Kiora, formerly EyeGate Pharmaceuticals, he guided the company through its initial public offering and multiple acquisitions in ophthalmic therapeutics.

Prior to EyeGate, From worked as CFO of Centelion SAS, a biotech subsidiary of Sanofi-Aventis, and spent several years in investment banking focused on life sciences at Bank of America Securities and Robertson Stephens. He holds a Bachelor of Science from the University of Western Ontario and earned his accounting designation from Wilfrid Laurier University.

The company will grant From a stock option award for up to 297,600 shares of Class A common stock as a material inducement for his employment. The options will have an exercise price equal to the closing stock price on the grant date and will expire after ten years. One-quarter of the options will vest after one year, with the remainder vesting in 36 equal monthly installments thereafter.

Founded in 2014, Vicarious Surgical develops robotic surgery technology designed to enable minimally invasive procedures using human-like surgical robots. The Waltham, Massachusetts-based company is backed by investors including Bill Gates and Vinod Khosla's Khosla Ventures.

You May Also Be Interested In